Skip to main content
. Author manuscript; available in PMC: 2023 Oct 3.
Published in final edited form as: JAMA Netw Open. 2023 Jan 3;6(1):e2251974. doi: 10.1001/jamanetworkopen.2022.51974

Table 2.

Summary of Clinical Trial Results

Clinical trial
COVE AZD1222 ENSEMBLE PREVENT-19 VAT00008 (stage 2)a
Treatment group Placebo mRNA- 1273 Placebo AZD1222 Placebo Ad26.COV2.S Placebo NVX-CoV2373 Placebo CoV2 preS dTM-AS03 (D614+ B.1.351)
Study population, No.
 Full-analysisb 15 166 15 180 10 797 21 583 21892 21 896 9961 19 907 6450 6472
 Per protocolc 14164 14287 8550 17 662 19398 19 400 8140 17312 5680 5736
End points, No. of events
 Primary: virologically confirmed symptomatic COVID-19 744 55 184 141 895 443 63 14 89 32
 Secondary: severe COVID-19 106 2 10 1 176 46 4 0 2 3

Abbreviation: mRNA, messenger RNA.

a

Results from stage 2 report on the bivalent vaccine data only.

b

Indicates cohort of participants who had undergone randomization and received at least 1 dose of placebo or vaccine.

c

Indicates cohort of participants who were SARS-CoV-2 negative before the first dose and received the complete number of doses, with no major Protocol deviation.